Korean J Radiol.  2014 Aug;15(4):494-500. 10.3348/kjr.2014.15.4.494.

Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports

Affiliations
  • 1Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Korea. g1q1papa@korea.ac.kr
  • 2Department of Oncology and Hematology, Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Korea.

Abstract


OBJECTIVE
The purpose of this study was to determine the incidence and risk factors of infections associated with implantable venous access ports (IVAPs).
MATERIALS AND METHODS
From August 2003 through November 2011, 1747 IVAPs were placed in our interventional radiology suite. One hundred forty four IVAPs were inserted in patients with hematologic malignancy and 1603 IVAPs in patients with solid tumors. Among them, 40 ports (23 women and 17 men; mean age, 57.1 years; range, 13-83) were removed to treat port-related infections. We evaluated the incidence of port-related infection, patient characteristics, bacteriologic data, and patient progress. Univariable analyses (t test, chi-square test, and Fisher's exact test) and multiple logistic regression analyses were used to determine the risk factors for IVAP related infection.
RESULTS
Overall, 40 (2.3%) of 1747 ports were removed for symptoms of infection with an incidence rate of 0.067 events/1000 catheter-days. According to the univariable study, the incidences of infection were seemingly higher in the patients who received the procedure during inpatient treatment (p = 0.016), the patients with hematologic malignancy (p = 0.041), and the patients receiving palliative chemotherapy (p = 0.022). From the multiple binary logistic regression, the adjusted odds ratios of infection in patients with hematologic malignancies and those receiving palliative chemotherapy were 7.769 (p = 0.001) and 4.863 (p = 0.003), respectively. Microorganisms were isolated from 26 (65%) blood samples, and two of the most causative organisms were found to be Staphylococcus (n = 10) and Candida species (n = 7).
CONCLUSION
The underlying hematologic malignancy and the state of receiving palliative chemotherapy were the independent risk factors of IVAP-related infection.

Keyword

Intravenous access; Cancer patient; Subcutaneous port; Infection; Complication

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Analysis of Variance
Catheter-Related Infections/*epidemiology/microbiology
Catheters, Indwelling/*adverse effects
Female
Hematologic Neoplasms/drug therapy
Humans
Incidence
Male
Middle Aged
Neoplasms/drug therapy
Palliative Care/statistics & numerical data
Retrospective Studies
Risk Factors
Vascular Access Devices/*adverse effects
Young Adult

Reference

1. Narducci F, Jean-Laurent M, Boulanger L, El Bédoui S, Mallet Y, Houpeau JL, et al. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. Eur J Surg Oncol. 2011; 37:913–918.
2. Fischer L, Knebel P, Schröder S, Bruckner T, Diener MK, Hennes R, et al. Reasons for explantation of totally implantable access ports: a multivariate analysis of 385 consecutive patients. Ann Surg Oncol. 2008; 15:1124–1129.
3. Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, et al. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol. 1998; 9:767–773.
4. Samaras P, Dold S, Braun J, Kestenholz P, Breitenstein S, Imhof A, et al. Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. Oncology. 2008; 74:237–244.
5. Pandey N, Chittams JL, Trerotola SO. Outpatient placement of subcutaneous venous access ports reduces the rate of infection and dehiscence compared with inpatient placement. J Vasc Interv Radiol. 2013; 24:849–854.
6. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49:1–45.
7. Gebauer B, El-Sheik M, Vogt M, Wagner HJ. Combined ultrasound and fluoroscopy guided port catheter implantation--high success and low complication rate. Eur J Radiol. 2009; 69:517–522.
8. Biffi R, Corrado F, de Braud F, de Lucia F, Scarpa D, Testori A, et al. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer. 1997; 33:1190–1194.
9. Brown DF, Muirhead MJ, Travis PM, Vire SR, Weller J, Hauer-Jensen M. Mode of chemotherapy does not affect complications with an implantable venous access device. Cancer. 1997; 80:966–972.
10. Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg. 1998; 22:12–16.
11. Lyon RD, Griggs KA, Johnson AM, Olsen JR. Long-term follow-up of upper extremity implanted venous access devices in oncology patients. J Vasc Interv Radiol. 1999; 10:463–471.
12. Wolosker N, Yazbek G, Nishinari K, Malavolta LC, Munia MA, Langer M, et al. Totally implantable venous catheters for chemotherapy: experience in 500 patients. Sao Paulo Med J. 2004; 122:147–151.
13. Caers J, Fontaine C, Vinh-Hung V, De Mey J, Ponnet G, Oost C, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Support Care Cancer. 2005; 13:325–331.
14. Ahn SJ, Kim HC, Chung JW, An SB, Yin YH, Jae HJ, et al. Ultrasound and fluoroscopy-guided placement of central venous ports via internal jugular vein: retrospective analysis of 1254 port implantations at a single center. Korean J Radiol. 2012; 13:314–323.
15. Gapany C, Tercier S, Diezi M, Clement C, Lemay K, Joseph JM. Frequent accesses to totally implanted vascular ports in pediatric oncology patients are associated with higher infection rates. J Vasc Access. 2011; 12:207–210.
16. Fätkenheuer G, Buchheidt D, Cornely OA, Fuhr HG, Karthaus M, Kisro J, et al. Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003; 82:Suppl 2. S149–S157.
17. Lebeaux D, Zarrouk V, Leflon-Guibout V, Lefort A, Fantin B. [Totally implanted access port-related infections: features and management]. Rev Med Interne. 2010; 31:819–827.
18. Teichgräber UK, Kausche S, Nagel SN. Evaluation of radiologically implanted central venous port systems explanted due to complications. J Vasc Access. 2011; 12:306–312.
19. Aitken DR, Minton JP. The "pinch-off sign": a warning of impending problems with permanent subclavian catheters. Am J Surg. 1984; 148:633–636.
20. Hinke DH, Zandt-Stastny DA, Goodman LR, Quebbeman EJ, Krzywda EA, Andris DA. Pinch-off syndrome: a complication of implantable subclavian venous access devices. Radiology. 1990; 177:353–356.
21. Lebeaux D, Larroque B, Gellen-Dautremer J, Leflon-Guibout V, Dreyer C, Bialek S, et al. Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature. Medicine (Baltimore). 2012; 91:309–318.
22. Di Carlo I, Toro A, Pulvirenti E, Palermo F, Scibilia G, Cordio S. Could antibiotic prophylaxis be not necessary to implant totally implantable venous access devices? Randomized prospective study. Surg Oncol. 2011; 20:20–25.
23. Karanlik H, Kurul S, Saip P, Unal ES, Sen F, Disci R, et al. The role of antibiotic prophylaxis in totally implantable venous access device placement: results of a single-center prospective randomized trial. Am J Surg. 2011; 202:10–15.
24. Gastmeier P, Geffers C. Prevention of catheter-related bloodstream infections: analysis of studies published between 2002 and 2005. J Hosp Infect. 2006; 64:326–335.
Full Text Links
  • KJR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr